certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: sioner of Patents, Washington, D.C. 20231 on this 21et day of January 2003. (Signature of person mailing) "Carol A. Senn (Typed or printed name of person) IN RE APPLICATION OF: ANABELLA VILLALOBOS, ET AL.

APPLICATION NO.:

09/976,347

Not Yet Assigned

FILING DATE:

OCTOBER 12, 2001

Group Art Unit:

1614

TITLE: COMBINATION USE OF ACETYLCHOLINEST-

ERASE INHIBITORS and GABAA INVERSE AGONISTS FOR THE TREATMENT OF

COGNITIVE DISORDERS

Commissioner for Patents Washington, D.C. 20231

RECEIVED

JAN 2 4 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEME PURSUANT TO 37 C.F.R. § 1.97 ET SEC

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445. A prompt and favorable response is earnestly solicited.

Respectfully submitted,

January 21, 2003

ene W. Appleman ttorney for Applicant(s)

Reg. No. 35,428

Pfizer Inc Patent Department, 5th Floor 150 East 42nd Street New York, NY 10017-5755 (212)733 - 3552

USERS\DOCS\LA21952\LPJWA\48O501!.DOC / 197933 / PC10803A INFO DISC STMT VILLALOBOS